Healthy, Microbiome
Conditions
Brief summary
This study is to evaluate whether Muno-IgY is effective in enhancing immune health among adults over a six week period.
Detailed description
The goal of this single-arm interventional trial is to evaluate the safety and effectiveness of Muno-IGY in a sample population of 20 healthy adults over a six week period. The intervention will be compared to a baseline before ingestion of the supplement with both qualitative questionnaires, a daily diary, and microbiome data gathered by the SIMBA and LIMBA capsules.
Interventions
DIETARY_SUPPLEMENTIgY supplement
Ingesting the immune supplement over the experimental period
Sponsors
IGY Immune Technologies & Life Sciences Inc.
Nimble Science Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
1. Aged 18-65 years old at the inclusion of the study, both female and male subjects. 2. Signed Informed Consent; willing and able to comply with study procedures. 3. Willing to maintain their diet and physical activity levels during the study. 4. Able to swallow a 25mm x 9mm sized capsule
Exclusion criteria
1. Use of regular prescription medications, including antihypertensives, anti-inflammatory drugs, corticosteroids, immunosuppressants, antidepressants, antipsychotics, anti-diabetic medications, and anti-arrhythmic agents, which in the opinion of the investigator, would adversely affect study safety or outcome. 2. Prior gastrointestinal disease, surgery, or radiation treatment which, in the Investigator's opinion, would lead to intestinal structuring or obstruction with a risk of capsule non-excretion, including, e.g., achalasia, eosinophilic esophagitis, cancer diagnosis or previous esophageal, gastric, small intestinal, or colonic surgery. Appendectomy or cholecystectomy more than 3 months before the screening visit is acceptable. 3. History of known structural gastrointestinal abnormalities such as structures or fistulas which may lead to mechanical obstruction. 4. Use of any medications in the week prior to the SIMBA or LIMBA capsule ingestions, unless part of regular treatment, that could substantially alter gastrointestinal motor function (e.g., opioids, anticholinergics, GLP-1 analogues); laxative and prokinetic use is allowed if it is kept unchanged in the week prior to the SIMBA and LIMBA capsule ingestions. Proton pump inhibitors (PPIs) are allowed provided a wash-out period of 48 hours is respected before swallowing the capsules and PPI treatment is resumed only 4 hours thereafter. 5. Organic motility disorder, including gastroparesis, intestinal pseudo-obstruction, systemic sclerosis, Ogilvie's syndrome. 6. Any significant gastrointestinal, heart, liver, lung, kidney, blood, endocrine or nervous system disease, which in the opinion of the investigator, would adversely affect study safety or outcome. 7. Cancer diagnosis or treatment within the past year (non-melanoma skin cancers are acceptable). 8. History or diagnosis of immunological or infectious disease (hepatitis, tuberculosis, HIV, Parkinson's). 9. History of oropharyngeal dysphagia, or other swallowing disorder with a risk of capsule aspiration. 10. Antibiotic use (except for topical use) ≤ 12 weeks prior to screening. Potential participants may be eligible once a 12-week washout is completed. 11. Consumption of probiotic or prebiotic supplements within 1 month prior to screening. Potential participants may be eligible once a 1-month washout is completed. 12. Any prior Fecal Microbiota Transplantation. 13. Colon cleanses/bowel prep for 2 weeks 14. Pregnant or breastfeeding. 15. Planning to become pregnant. 16. Alcohol or drug abuse. 17. Egg allergy 18. Vegan diet, or other diet where ingestion of eggs is not suitable 19. History of less than 3 bowel movements per week. 20. Are scheduled for an MRI at any time during the study. Potential participants may be eligible to participate once their MRI procedure is completed
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Primary Outcome | Through study completion (Baseline to the end of the interventional period), an average of 6 weeks | To assess the safety of Muno-IgY™ in the small intestine. By monitoring the number of participants with treatment-related adverse events as assessed by CTCAE v4.0 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Secondary 1 | Through study completion (Baseline to the end of the interventional period), an average of 6 weeks | Investigate the association or determine if changes in the small and large intestine occur and fecal microbiomes through metagenomic analysis |
| Secondary 2 | Through study completion (Baseline to the end of the interventional period), an average of 6 weeks | To assess the bioavailability of the Muno-IgY, using the SIMBA capsule as a tool for sample collection |
Countries
Canada
Contacts
Primary ContactGwen Duytschaever Duytschaever, PhD
Backup ContactIsaac Wong, MBT
Outcome results
None listed